[
  {
    "ts": null,
    "headline": "2 Beaten-Down Stocks to Buy and Hold",
    "summary": "Moderna has a deep pipeline of promising mRNA candidates that stand to boost business.  Regeneron is looking at label expansions for its main product as well as clinical progress elsewhere.  Here are two great examples to consider: Moderna (NASDAQ: MRNA) and Regeneron Pharmaceticals (NASDAQ: REGN).",
    "url": "https://finnhub.io/api/news?id=d997ab110453747799205f4839ec382006208458707934721f37ed2ad31debd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751715900,
      "headline": "2 Beaten-Down Stocks to Buy and Hold",
      "id": 135766841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna has a deep pipeline of promising mRNA candidates that stand to boost business.  Regeneron is looking at label expansions for its main product as well as clinical progress elsewhere.  Here are two great examples to consider: Moderna (NASDAQ: MRNA) and Regeneron Pharmaceticals (NASDAQ: REGN).",
      "url": "https://finnhub.io/api/news?id=d997ab110453747799205f4839ec382006208458707934721f37ed2ad31debd9"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Moderna Be in 10 Years?",
    "summary": "After soaring in early pandemic days, Moderna has fallen into the doldrums.  An explosive phase of growth may be ahead thanks to several potential product launches.  A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).",
    "url": "https://finnhub.io/api/news?id=b2b87c520d325b3dc7d2fad570245d3ac6300ff1376f20a0c98d2482bdfef3d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751706600,
      "headline": "Where Will Moderna Be in 10 Years?",
      "id": 135769569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "After soaring in early pandemic days, Moderna has fallen into the doldrums.  An explosive phase of growth may be ahead thanks to several potential product launches.  A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).",
      "url": "https://finnhub.io/api/news?id=b2b87c520d325b3dc7d2fad570245d3ac6300ff1376f20a0c98d2482bdfef3d5"
    }
  }
]